Placeholder Image

字幕表 動画を再生する

  • We're going to be moving the session now, Thio.

  • Bit more different perspectives.

  • I might go straight home professor here in school, public health at university and I just want to say, uh also a welcome as, ah, one of the program planning Committee members not only to you here in the audience, but to actually our audience in Europe.

  • Good afternoon to you.

  • We have people on the Webcast there, and I want to start out by actually offering a personal perspective as I stand here today to moderate this because I don't stand here with great expertise in human participants and studies other than I've been both and both sides of those.

  • But I actually stand here today as someone who realizes that between now and the time I take my last breath, I may very well be a candidate as a participant in a study of great importance of which I am going to have for all the reasons already outlined this morning, potentially some issues about how I consent or don't consent to that study.

  • But more importantly, I'm like many of you in this room.

  • I have family members or family friends who are by every definition mentally ill who are incapacitated from a standpoint of making cognitive decisions that we would all agree are made with full informed consent because of whatever status they might have.

  • I have family members who have severe chemical abuse problems who at times may very well be able to make good decisions and canned.

  • And so it's very hard for any of us up here.

  • Just to stand here is academicians, because in a sense, this is all really about all of us about all the time.

  • And so today, what we wanted to do is a part of the program Planning Committee is actually scheduled a session here, which is entitled Multiple Perspectives on the National Debates and Consent Challenges, knowing that there is not a right answer, but we sure it can learn a lot.

  • And today we're very fortunate to have four different experts with us, all who will provide a perspective on.

  • I'll introduce each one of them at the time that they would come up.

  • They will give a 10 minute presentation.

  • They've all agreed to keep it to 10 minutes out of courtesy for their fellow speakers and so that we can also open it up, then for a dialogue with this audience, which we realize is very important a time then that they're done.

  • We will ask them to come all up to sit up here as well as our two morning speakers.

  • And then it's open for all questions and coming.

  • So our first speaker today eyes to abjure Holding, who is the executive director of the National Alliance on Mental Health, Minnesota.

  • Su has devoted her career to changing laws and attitudes that affect people with disabilities and their families.

  • At the National Alliance on Mental Illness, Minnesota, she has focused on the stigma surrounding mental illness and the broken system of care for Children, adults with mental illnesses.

  • Over the past 25 years, Sue has successfully fought for community and family support and for the laws that enable people with disabilities to fully participate in society.

  • She has a very important and supported background and that she held positions with the Ark Minnesota.

  • She understands policy is having served in U.

  • S.

  • Senator Paul Wellstone staff and also at the Pacer Center.

  • We're very honored to have her with us today and sue the floor is yours for the next 10 minutes.

  • Thank you.

  • All right, so I'm gonna talk fast.

  • Um, first, I just want to make sure everyone knows so.

  • Mental illness affects one in five people in every given year, and it affects everyone.

  • Children and adults, men and women, people from every race, ethnicity, religion and political parties, Democrats and Republicans alike.

  • And it affects people from every profession football players, physicians, teachers, artists, musicians, meteorologists.

  • The symptoms disrupt a person's thinking, feeling, mood, ability to relate to others and daily functioning So you can understand how these symptoms could interfere with decision making.

  • But mental illnesses air on a continuum, and not every person with a mental illness becomes disabled by their illness or has the capacity to consent compromised?

  • We prefer to focus on people's strengths using words like courage and determination, not weakness or incompetency treatment.

  • Effectiveness ranges anywhere between 60 to 80% and we know that early identification and treatment can lead to recovery and prevent them from becoming disabling.

  • I do want to note that treatment involves much more than medication and includes therapy, diet and exercise.

  • Complementary therapies such as mindfulness training, social connection to friends, and families and having a reason to get up in the morning, such as having a job, attending school or volunteering.

  • Unfortunately, in our mental health system here and frankly across the country, we don't use the public health approach to treating people with mental illnesses first.

  • We don't identify people early.

  • They live with their symptoms an average of 10 years before seeking treatment.

  • 72 weeks for a young person experiencing their first psychotic symptoms.

  • Second intensive treatment isn't provided until someone has been hospitalized or committed numerous times.

  • Assertive community treatment and evidence based practice isn't made available until someone has become disabled due to their illness and has a history of homelessness or hospitalizations.

  • It's akin to waiting to treat people with cancer until they hit Stage four.

  • When we discuss involving people with merit, serious mental illnesses and research, we need to keep in mind the continuum and that people are frankly much sicker when they come into our public mental health system.

  • And by the time people are before the courts, they're extremely ill.

  • In Minnesota.

  • Every year, about 4300 people are committed to treatment for their mental illness.

  • Now, the commitment law is about involuntary treatment.

  • Nat Competency Guardianship is about competency, and this is a very important difference.

  • In order to be committed to treatment at least a Minnesota, an individual must have a diagnosis of a mental illness, and there must be a strong likelihood that the individual will harm themselves or others, as evidenced by failure to obtain food, clothing, shelter our Medicare medical care as a result of their illness or inability to obtain these things.

  • And it's more probable than not that the person will suffer harm, serious illness or significant psychiatric deterioration as a result of not receiving that medical care.

  • Or there's a recent attempt or threat to physically harm themselves or others.

  • Or there's recent conduct involving significant damage to substantial property, and there is no less restrictive way for the person to get treatment.

  • So it's important to remember that people are committed to treatment for a variety of symptoms, including psychosis, but also due to serious depression and thoughts of suicide.

  • Most people in Minnesota are committed for up to six months and again, commitment is for mental health treatment, not competency.

  • And it's not guardianship.

  • As a matter of fact, few people with serious mental illnesses, including people with schizophrenia, are under guardianship because of one word.

  • Recovery.

  • Judges are very reluctant to take away people's rights to make the decisions about their lives.

  • When it's often a temporary situation, many people begin to feel better in a couple of days or weeks once they get treatment.

  • And many people whose symptoms decrease and are moving towards recovery are placed on a stay of commitment, meaning if they continue to follow their treatment plan, their commitment will be discharged.

  • The Commitment Live doesn't really talk about competency, except to say that an individual can consent to other types of treatment if the physician believes the person's competent while under commitment.

  • There is nothing in law that prevents the individual from signing contracts, using their credit card, taking out loans and more.

  • And there's nothing that prohibit companies or entities from making them accountable for their actions.

  • So you need to keep this in mind as we turn to discussing allowing people with mental illnesses to participate in research.

  • Even in 2015 our understanding of the brain is limited and research is really in the beginning stages.

  • Technology has helped in terms of stronger memorize, but even then reviewing the brain of the 30,000 foot level without a better understanding of the brain and increased funding for research, new treatments for mental illnesses are limited.

  • But people with mental illnesses and their families hold out hope that new research will emerge and lead to better outcomes, which will allow our society and communities to benefit from their gifts and talents.

  • We need research of the brain and research to find better mental health treatment, not just medications, but different forms of therapy and technology.

  • Tom Insel, who just stepped down as the head of N Ame age, wrote that quote.

  • We need to be humble.

  • The science of mental illness is still in its infancy, and our treatments, while helping many to get better, do not help enough to get well.

  • So you have people who have not gotten better, some who have gotten better, but not well, but all of whom desire recovery.

  • It could be that the side effects of medication are just too difficult, but at the same time the symptoms interfere with their recovery.

  • They want to find a better treatment so that they can get better and lead full lives.

  • There are also people who believe in the greater good, if you will.

  • I'm reminded of the quote that we're here to plant the seeds of trees under whose shade we will not sit.

  • They wanted to be better for the next generation.

  • We know this is true for people with cancer whose only hope is a new treatment, and they know it really may not help them, but will increase understanding and treatment of that particular cancer in the future.

  • It is no different for people with mental illnesses.

  • Despite having two very good reasons to participate in research, there is still hesitancy.

  • We want to make sure that although someone with a mental illness hasn't been deemed incompetent by a court, that they're protected nonetheless initially when first hospitalized under a commitment, a person's ability to consent may be compromised.

  • And of course, it could be compromised any time that they're symptomatic.

  • And while we shouldn't unilaterally prohibit people with mental illness from participating in research at this time, we should use the tools that exists to determine if they're competent to make decisions.

  • There's a couple of tools that you be a CC, the MacArthur Competency Assessment Tool for clinical research.

  • A very small percentage of people stay committed for excuse me for a very long time due to lack of insight.

  • And they stopped treatment once the commitment is lifted and then they quickly deteriorate.

  • But is it fair to deny the people with the most serious mental illnesses new treatment that might work better and could help them achieve recovery?

  • And while they may not have insight, they may want to change their outcomes.

  • A few people with mental illnesses are under guardianship, so there aren't alternative decision makers or legally authorized representatives.

  • Even worse, our Mel health system has systematically excluded family members from being involved in a loved one's care or even being able to obtain basic information.

  • And they often use HIPPA as a shield.

  • Even though it's, NAMI likes to say, HIPPA doesn't require you to be stupid.

  • This leaves many people with mental illness, is even more vulnerable and participating in research, because often family members aren't allowed to be involved.

  • So there's no advocate, if you will in the discussions around consent.

  • So we need to either include families or make sure a person has an advocate in the process of agreeing to participate and research, and they also want to just mention that prior to the A c a.

  • Especially Medicaid expansion.

  • Participating in research for many was the only way to access treatment.

  • Another issue is that the method of asking for consent is not necessarily effective.

  • Simply handling someone a form to read and sign isn't the best way to ensure that someone understands what they're signing and understands the benefits and risks.

  • More should be done to ensure that someone with a melon illness has information and understanding of the information to actually make a decision.

  • Just as there is a movement and discharge planning to use the teach back method so there should be here.

  • Studies suggesting adding multimedia tools also improve understanding.

  • So I'm nearing the end of my time.

  • But I want to urge people not to paint people with mental illnesses with one brush.

  • There are many who can consent to participate in research and you are doing it for all the right reasons.

  • Let's just take extra care that they understand what it means to participate in a particular research study, especially the risks and benefits that they have a family member or advocate with them, and that we have determined outside of a courtroom that they're competent at that moment to consent.

  • But finally, let's not deny people with mental illness and their families the hope for recovery that can come through research.

  • Thank you.

  • Thank you, Sue, for that.

  • Very good.

  • Start to the multiple perspectives.

  • Next, we're going to hear from someone who's already asked a question this morning and someone who has been referred to on multiple occasions because of her well recognized international expertise.

  • Bar Beer is a professor at Harvard Medical School, senior vice president of research at Brigham and Women's Hospital, director of regulatory foundations, ethics and law at Harvard Catalyst and a former chair of the secretary's Advisory Committee on Human Research Protections.

  • Department Health Human Service is Barbara is also co chair of the Partners Healthcare Committee and Conflict of Interest.

  • In addition to our academic responsibilities, she's also was elected to the board of directors of the Association for Accreditation of Human Research Protection programs.

  • Serving is this president's from 3 4007 She's currently a member of the Double A M C.

  • A U Advisor Committee and financial conflicts of interest in clinical research and a member of the National Academy of Science Committee on Science Technology in the Law.

  • It's really an honor to have you here with us today and turn it over to Barbara.

  • And I want to thank the organizer's for inviting me.

  • Uh, it's really a pleasure to be here, and we'll be up in a minute.

  • Hopefully, yes.

  • Under consent.

  • Mmm.

  • That's it?

  • Yeah.

  • Good.

  • So, um, I thought today I'd take a bit of a step back and talk about general consents, not consents specifically for, um, for vulnerable participants.

  • But I will say that I have no financial conflicts of interest while we're waiting.

  • I have lots of employment and other opportunities that inform my opinions on having just come from the N s yesterday.

  • All of those air quote relevant.

  • Um, and I am very opinionated.

  • And therefore, um, I gave you, although we cannot see it now, you can, um my conflicts.

  • So I'm gonna pick up where Jeff left off a little bit.

  • Which is to say that informed consent is very, very hard to achieve.

  • And we have never really done a very good job of it, and I think we need Thio.

  • Think through where we are with informed consent, and it's a significant problem way beyond that of vulnerable populations.

  • And if we're doing a terrible job on quote, normal people were doing a disastrous job on vulnerable individuals.

  • There are no standard processes by which elements are presented and described, and the documentation of comprehension at the time of consent or thereafter is not required.

  • And it's rarely obtained.

  • And there are very few validated methods for comprehension and even fewer for long term comprehension.

  • We may ask somebody week later what they remember, but we don't ask somebody six months into a trial what they remember.

  • Um, there is teach back.

  • It's very poorly implemented.

  • It is successful when done right, But there's very little effort, Uh, in in this Theo NPR M, which we heard about this morning, has the goal, which is laudable quote to facilitate perspective, Subject's decision about whether or not to participate in a research study, thereby enhancing autonomy.

  • Um, I eat that the subjects are appropriately informed and they suggest three primary changes, which I'm summarizing stricter new requirements were quite regarding required information to prospective subjects.

  • Organized the document to provide sufficient detail but also facilitate understanding and present core information first, including only the required elements of consent and including all other information in the appendices.

  • And that's the approach.

  • Here are the required information of the consent elements.

  • These have been traditionally required.

  • Everybody here is probably familiar with, um, even this to to this list, which I won't read.

  • The NPR M adds a statement about whether or not the subject's data will be used for future research studies.

  • If the identify IRS are removed, Um, there are additional consent elements that one must use in certain situations.

  • And two that the NPR M adds three Maur additional elements.

  • Well, I would venture to say that the basic elements have informed consent her largely and changed with one new element.

  • And the three additional elements is not going to improve the informed consent process that we're currently engaged in.

  • We're not going to get to a state of better information and better content appreciation by simply adding to the list of elements.

  • So the changes to the informed consent document they require now that only required language that speaks to the elements of consent being the document, other elements in dependencies and that the final consent forms will be posted on a federal website somewhat after again.

  • I would argue that the organization of the document with the core information first and then followed by the dependencies later posting is not gonna answer our issues.

  • So what What are we going to dio the NPR m is not gonna fix it.

  • So I would argue for a few different approaches to be tested.

  • First of all, explore research context that may not require individual informed consent, but rather public education, coupled with governance, to ensure that that education is disseminated and efficacious, You could have a risk based, minimal risk research and potential potentially toe opt out.

  • I'm not going to talk about, as we say issues with tissues.

  • I'm not gonna talk about by a specimen research, but this is one where one might think about it.

  • Reemphasize and prioritize.

  • Public health is a core component of the Belmont principals currently thoughtfully embedded in justice but not brought out as a real principle.

  • And then I should say that other public education campaigns have been effective, even if people are, um, somewhat cynical about that different approach, However, for higher it's research that requires informed consent, interventional studies, blinded control studies, et cetera.

  • And I think that they're one really needs to re invest time in a one on one appreciation of the informed consent process.

  • It's the only thing that really makes a difference and to reframe.

  • The focus is, Jeff said earlier on investigator responsibilities and integrity.

  • And here our list, the sack up comments that we worked on together and then commit to plain language summaries, health and new mercy principles.

  • In all, communication with participants here are the CDC, Clear communication principles.

  • They're not so difficult.

  • And, uh, but we don't do this in general.

  • We don't do this with each other, and we don't take care.

  • Thio ensure that our communications are playing language and again to endorse numeracy principles rather than not, there are alternative approaches.

  • I think that we should think about investing in preparation of the community so that they know what they're looking at, what they're working on and what they're about to, um, uh, consent to.

  • We've developed a whole set of information in order to help people prepare for that conversation with an investigator.

  • Um, and it's available in 15 languages.

  • You can download them, Um, and those air flat brochures.

  • They're plain language.

  • They're appropriate, but they're flat.

  • You could also have a Web based, um, sort of preprinted ve materials.

  • This is 14 individuals preparing for research and to the research participant and, um, and Children's Hospital.

  • Boston took the initiative to do a Sophie's Science Project, which is a comic book explaining participation in clinical research.

  • There are lots of things we're not doing now and not thinking about creatively.

  • Um, and we don't really provide that flexibility to explore, uh, consent materials.

  • And then there's the use of multimedia tools for icy processes.

  • I went for informed consent process is online.

  • In one second, you can get 124,000 YouTube videos on M arise.

  • Imagine if we were to take some of that information, cut it down to 35 40 seconds.

  • So the people had a visual image of what they would enter when they have a are undergoing an ATM or I, um, and what the risks and benefits would be that we could do sort of with, like, a Harry Potter, uh, newspaper so that you get to m r I and then you click on it and it comes up so that you understand where you're going with it.

  • Um, these kinds of things we're not exploring And that is where I'd like to look at as a research agenda going forward to think about public education coupled with governance and perhaps an opt out higher risk research, embedding investigator responsibilities, plain language communication, investing in preparation, flexibility to explore consent materials and interactive multimedia.

  • I see informed consent platforms once you get there than your immediately begging the question of e consents, Elektronik consents, and one can use those.

  • It's another, uh, effort that we should think about.

  • Um and, uh, these are ideas.

  • But in order to really know when they work, how they work when we would want them to be employed, we really need to collect the data.

  • And in order to do that, we need the right methodologies to do so.

  • Thank you.

  • Thank you, Barbara.

  • Now moving on to one of our own here from University Minnesota, Uh, at another perspective to this is Carl Elliott, who's professor the Center for Bioethics in the Pressure in the Center for Bioethics and Department of Pediatrics and affiliate faculty member in the Department of Philosophy and School of Journalism.

  • Mass Communications at the U.

  • Of M.

  • Carl is the author or editor of seven books, including White Coat, Black Hat, Adventures in the Dark Side of Medicine, published 2010 and Better Than Well, American Medicine Meets the American Dream in 2003.

  • His articles have appeared in The New Yorker, The Atlantic Monthly, London Review of Books, Mother Jones and Your Times and the New England Journal of Medicine.

  • In 2011 the Austen Riggs Center awarded him its Erickson Prize for Excellence and Mental Health Media.

  • He is a fellow the Hastings Center, former network fellow at the Saffir Center for Ethics, Harvard University and a member of the Institute for Advanced Study in Princeton, New Jersey Carl, they're happy to have you.

  • Thank you all for coming.

  • And thanks for inviting me.

  • I appreciate the invitation.

  • So, um, this term I've been teaching a new course over in the honors College honor seminar.

  • It's on medical research scandals.

  • So for three months has been all scandals all the time.

  • It's the all scandal Channel, uh, two scandals a week for an entire semester.

  • And we've started with the classics to ski the Willowbrook Homes Berg, the unfortunate experiment in Auckland, New Zealand, and going right up to the present day and has really been the first time I've had a chance to read about so many different research scandals back to back.

  • And I thought, Maybe I start today with some sort of unsystematic observations about what I've learned from that course.

  • So, uh, first observation.

  • Whistle blowers are very rare, even in the most dangerous the institutions.

  • This actually surprised me.

  • But it's true, and it's true whether you're talking about ah drug company or a C.

  • R O or a government agency or a university.

  • Dissent is rare When there is dissent, the dissenters usually keep it in house, and they always never blow the whistle to the press.

  • So that's first observation.

  • Second, um, when someone does blow the whistle, usually nobody listens.

  • Often it takes years to get any kind of action.

  • I mean, looking back, as shocking as the Tuskegee Syphilis study seems now, It took Peter Buxton six years to get a reporter actually interested in reporting that story.

  • And with the cancer trial scandals in the eighties and nineties at the Fred Hutchinson Cancer Sentiments Seattle it took John Pasando, the whistle blower there nearly 20 years.

  • Which leads to the third thing.

  • When scandals do happen, the wrongdoers are rarely punished.

  • In fact, they're often rewarded.

  • You can see this, particularly when you look back at the scandals of the sixties and seventies.

  • So, for example, Saul Krugman, you might remember fed Hepatitis eight, a mentally retarded Children at the Willowbrook State School.

  • Um later became president of the American Academy of Pediatrics.

  • John Cutler, who was one of the architects both of Tuskegee and of the Guatemala Syphilis Studies, later became professor in dean at the University of Pittsburgh and Chester South.

  • Um, who injected live cancer cells into elderly patients of the Jewish Chronic Disease Hospital, became president of the American Association for Cancer Research.

  • Now those are old cases.

  • But even today, most most researchers who are accused of wrongdoing land on their feet and forthing.

  • Institutional officials almost never do the right thing.

  • In fact, I don't think all term, we found a single case where a medical school Dean has been told of wrongdoing and responded in a decent and honorable way.

  • Instead, the reaction is almost always defensive.

  • Cover it up, keep it quiet.

  • And above all, don't tell the patients.

  • Now we've had our share of scandals here, the you, of course, the most notable of which have occurred in our department of psychiatry, where a young man named Dan marking Seuin tried to decapitate himself after being coerced into an industry funded any psychotic study.

  • When suiting, this audience knows about the markings in Case, um last spring to reviews.

  • One of that case in particular, found evidence of coercion, profound conflicts of interest, ah, superficial, porous system of research oversight and a climate of fear and intimidation in the Department of psychiatry that made staff members afraid to speak up on behalf of patients.

  • Now, if you look at our scandals in a lot of ways, they fit that historical pattern.

  • It took 11 years for Dan Mortenson's mother to get any kind of indication that fits the pattern.

  • Nobody at the University of Minnesota has been sanctioned or punished in any way for the wrongdoing.

  • Again, that fits the pattern.

  • University officials, including the president, misled the public with deceptive statements for years before they were finally exposed again.

  • That fits the pattern.

  • Now.

  • Where the University of Minnesota stands out, I think, is how consistent its response has been over such a long period of time.

  • It does matter who was speaking.

  • Could be the president could be the Board of Regents.

  • Could be the dean.

  • Could be the general counsel.

  • Could be the communications office, no matter who it waas.

  • The answer was always the same, and that answer was, We did nothing wrong.

  • We have been exonerated and went on answering your questions.

  • So there was that.

  • But it wasn't just that the university has been remarkably aggressive towards its critics.

  • I don't just mean the fact that the university filed a legal action against Denmark, Kingston's mother, demanding that she paid the University of Minnesota $57,000.

  • Although that's pretty aggressive.

  • I've never come across this term anyway, another university that was willing to file a legal action against a dead research subjects family.

  • What I'm talking about here, the U.

  • Is the strategy of defending yourself by trying to discredit and smear your critics.

  • Now, as you can see, a lot of that has been directed at me, of course, and that message has been consistent no matter who it's come from.

  • From the PR office to the dean, that message is, I was lying.

  • I was distorting the facts.

  • I was on a crusade against the university.

  • I was just trying to sell my books.

  • Apparently, the notion that anyone at the University of Minnesota might actually be trying to protect research subjects was so bizarre and unfamiliar that it never even entered their minds now because I said, a lot of that was against me.

  • But it wasn't all me, for example, when Nikki Jerry, a psychiatric nurse at Fairview and by the way, you're a member of our I R B at the university for over 17 years.

  • When Nikki Jerry spoke to reporter last year about the markets in case the university's PR office went on the attack against her as well, saying that she had no credibility to speak about the case.

  • Now Nicky knows how to defend herself so dull.

  • I I'm a tenured professor here.

  • I have some protection, but patients don't have that kind of protection.

  • Some of you may know of the ongoing controversy regarding a patient named Robert Humor.

  • Robert was coerced into testing an unapproved any psychotic while he was confined to a locked unit at Fairview under a 72 hour emergency hold.

  • And years later, when he finally worked up the courage to speak to a reporter about his case, the university Communications office access his medical records and then used his private medical history, um, in an effort to try and discredit him.

  • And since that kind of action has been since sanction and endorsed by the dean, I can assume that we'll be seeing more of that in the future.

  • Now, today, since those two external reviews, of course, the PR strategy has changed.

  • It says.

  • We're reforming.

  • Our policies were looking forward.

  • This conference, for example, is proof of our good faith.

  • But the fact is the problem here.

  • The U has never been our policies.

  • It's been our people.

  • That's why when the legislative auditor reviewed the markings in case, he singled out the actions of the university leaders as the single most troubling aspect of the scandal.

  • And, of course, that's never been on the agenda from the very beginning of this controversy.

  • Up until today, the university is sound a single, consistent but unspoken message.

  • Here's what that unspoken message says.

  • If you break, the rules, will look the other way.

  • If you harm a research subject will cover it up.

  • Somebody speaks out.

  • We will do our best to harass and discredit them and make them regret it.

  • And until that message is admitted and disavowed and the people responsible for it had been sanctioned, I can't see anything at this university changing.

  • Thank you, Thank you, Carl.

  • I'm sure we will have quite a bit of additional discussion here.

  • Related that our last speaker is Richard Sharpe.

  • Richard is, uh, Fester and director of the Bio Medical Ethics Program Center for Individualized Medicine Bioethics Program and the Clinical and Translational Research Ethics Program at the Mayo Clinic.

  • He has studied a variety of topics and biomedical ethics, including the integration of genetic technologies into patient care, best practices for clinical ethics, consultation, financial conflicts of interest and ethical dimensions of patient advocacy.

  • Richard frequently advises healthcare organizations and ethical issues and has served on advisory committees for the National Institutes of Health Institute of Medicine and the U.

  • S Environmental Protection Agency.

  • Thank you.

  • Very glad to have you here today.

  • Thanks.

  • Thank you.

  • I appreciate the opportunity to be here.

  • It appears I've drawn the short straw with regard to the ordering of the talks, but indeed want Thio talk you through some issues that our group has been thinking about for some time and also want to say I'm going to be talking about some complex issues that have to do with responding to research scandals and be very clear that my comments are not directed specifically at the case that we just heard Dr Elliot Review.

  • That's not a case that I have that kind of acquaintance with a familiarity with.

  • And so I'm not directing any comment specifically to that case.

  • I want to raise a slightly larger, more abstract question here.

  • And that question is when a research scandal does occur and people come forward from the community and from the public and say Why is it that we should trust that your university and the researchers that are at your university are people of integrity, that they're individuals that are acting in the right sorts of ways.

  • They're doing the right things by way of their patients and their research volunteers.

  • When we seek to answer that question, how good are the answers that we provide now?

  • We heard from our speakers this morning that we have a system that was referred to as one that has been extraordinarily successful in providing protections to research volunteers.

  • But when something goes wrong and questions get called how good our answers.

  • And I think what we heard in the talks this morning were that those answers cost her around a couple of main points.

  • The first is that we have a committee, right.

  • We have a committee that is staffed by university employees and researchers that reviews every protocol includes one member of the community.

  • As a matter of fact, in addition to that, and those individuals have signed off on the ethically appropriate nature of the study being conducted.

  • That's part of the answer.

  • The other part of the answer is that we asked people whether they want to participate in these studies for the most part.

  • But we as we heard by and large, many people make decisions about participation that are inherently uninformed, not a particularly compelling answer.

  • So if we if we are called out on that question, why should we trust that the research supported by your university is in fact, ethical and done by people of integrity?

  • If our answer to that is, we have a committee and we asked people, how compelling is that answer?

  • And I want to suggest that that's not very compelling at all.

  • And honestly, if you do find that answer compelling, I said I would suspect that means you were brought up in a good neighborhood.

  • Quite honestly, on I don't mean that in a facetious, joking way, I think that really is a reflection of the kind of assumptions that we bring the medical institutions more generally.

  • If that's sufficient as an answer to you, it means that you probably have a very good relationship with medical institutions.

  • So we started to ask this question.

  • We said What?

  • What can we learn from other areas of society that deal with similar types of questions?

  • And our team asked this question.

  • What might we learn from non medical sectors in which there are occasionally crises of public confidence that can engender more systematic assaults on the those institutions.

  • So we went to exempt, for example, two individuals that are in the food industry and asked them how they respond to national crises associated with E.

  • Coli threats.

  • When GIA Poll today, for example, recently had its scare around E.

  • Coli, a zit turned out.

  • Some people stopped going to restaurants for a small amount of time.

  • But there was no national crisis that was a result of that.

  • It wasn't as though all of us stopped eating fast food for months on end.

  • When an aircraft crashes and it goes down, people respond to that.

  • And do is that I think are very different from the ways in which health care institutions respond to their crises when they occur.

  • When a person dies in a clinical trial, that response looks very different from the response of the airline industry to when a flight goes down.

  • And so we decided that we would convene a group of leaders in these non medical industries, ask them to come together and help it to advise us in terms of ways in which the health care industry might do a better job of responding to crises of public confidence.

  • And what we learned from them was that the things that they find to be most successful are things that health care institutions in general don't do a very good job with.

  • So they told us, for example, that it's critical that the public understands your mission and understands in their terms what it is that you're trying to accomplish, They said.

  • It's key that there be transparency about the potential benefits and risks of the things that you do right.

  • The dangers of food contamination need to be evident to the public and in a way that perhaps is very different from the ways in which the dangers of participation in medical research are currently evident to the public that there needs to be shared vocabularies and a habit of listening to your constituents to understand what their needs and concerns, maybe, and then in addition, if you rely solely upon government regulators to ensure that the work that you're doing embodies the highest of ethical standards, that you're falling far short of what the benchmark should be, that self regulation needs to be in place in a CZ well is one of our representatives from the airline industry, I remember very poignantly said, is that we rely on the government to regulate the airline industry.

  • Claims will be dropping out of the sky every day.

  • I just remember that so, so vividly because, frankly, it's scary to think about, but it actually is very important and so relevant to the conversation we're having this morning.

  • Compliance alone doesn't get us very far.

  • It's the integrity of those individuals that are charged with ensuring that human subjects are fully protected.

  • That's absolutely critical.

  • And the last point that we learn from them was that the system of oversight that you have has to be blamed free and non hierarchical.

  • If a person who was a grounds crewman has a concern about the safety of the airplane, that individual can shut down the entire flight.

  • We know that right, but we don't stop to think about what's the significance of that power that we vest in that individual who is sort of at the lowest level of the totem pole with regard to the operation of of the airline industry that it's not only the case, that individual that individual can stop the flight.

  • Everybody involved wants that person to step forward, and there's a system in place that allows them to step forward without fear of retribution.

  • Again, The contrast here between this this type of messaging that we heard and what I think is commonplace in medical and many medical institutions is really quite striking.

  • They talked to us a CZ well about the importance of differentiating between the tined of trust that's critical in moments of crisis and the kind of trust that you hope to establish more generally in particular, they talked about the importance of root cause analysis when some sort of crisis engendering event does occur, that there be effort to systematically evaluate what went wrong and that there be transparency and involvement from people that sit outside of that particular institution in the process commitment essentially being evidence that you want to ensure that this type of tragedy never occurs again again.

  • I think these are things that make a lot of sense.

  • I think there's a lot of common sense and body than the sorts of statements, but the contrast here was what really stood out to us.

  • The contrast between a typical response to a crisis in the context of the conduct of medical research and these types of crises that occur in nonmedical industries.

  • Then, lastly, as a result of the interactions that we had with these non medical experts, we began to think about some conceptual frames of reference that might help to guide health care institutions in promoting and establishing trust in times of crisis.

  • And here we were inspired by some of the literature that's come out of Europe that focuses on what is commonly referred to his promotion of a culture of safety.

  • And here you have several different stages with regard to what you might think of as the evolution of an emergence of a culture of safety.

  • I think this kind of conceptual frame of reference really applies very nicely to trying to establish a culture of integrity and ethical conduct in human subjects research as well.

  • Now most most universities aren't going to be sitting at the bottom end of this particular spectrum.

  • I don't think that many of us would look around at our universities and say that nobody cares about the protection of human research subjects, but I suspect that many of us probably have institutions that fit Maurine the second and third of these categories, where our efforts to improve upon patient safety are largely reactive to problems that we identify at some point along the way, that we don't necessarily take a more proactive stance with regard to ensuring subject safety and that we rely extensively on the third of these boxes.

  • We rely upon the system the system of compliance that we have in place and equate compliance with integrity in ways that I think may limit our ability to be more imaginative with regard to instilling public confidence in medical research.

  • And so these folks suggested to us that we think about ways in which we might become more proactive and Maur generative so that ultimately weaken become committed to the idea that promotion of subject welfare is simply a part of the way in which researches always done that.

  • Everybody's thinking about that all the time, not just when something goes wrong, not just because of the I R B asked them to think about those matters, but it's just part of the way in which business is done at research universities and here I want to close by asking you to think a little bit about the contrast between this farthest end of the spectrum this end of the spectrum in which we might suggest that this really embodies the full commitment to research, integrity and the current ways in which people think about institutional review boards and their roles.

  • Many institutions There's enormous resentment of Eire bees.

  • Irby Arby's are viewed as barriers to the conduct of human subjects, research as slowing down much needed medical research as staff, largely by micromanaging research administrators that are more concerned with institutional liability than the promotion of valuable research.

  • Maybe it's different here, but I I hear that elsewhere and think about the contrast that we have to overcome here if we are, in fact, to get to this more generative matter.

  • I think it involves increasing levels of transparency with the community and ultimately involves giving over some degree of power and control over the research agenda to community representatives as well in a way that I think that few institutions are really committed to doing so.

  • I would encourage, you know, the folks that are here at the University of Minnesota to think about what's happened recently as an opportunity to engender genuine formative, substantive changes here with regard to your systems.

  • It isn't very often that an opportunity like this comes along, and I encourage you to take advantage of it.

  • Thank you.

  • We could ask our speakers this morning to come on up now is the unique opportunity to have audience participation with, uh, really a true variety of expertise is and perspectives.

  • So with that, we have the microphones in the audience.

  • If you could raise your hand, why were assembling the panel and then we'll get the microphone to you.

  • Any questions here?

  • If not, I'm gonna start asking.

  • Here's okay.

  • We have over here, uh, over in this corner here.

  • I'm sorry.

  • I'm trying to look and see you.

  • Raise your hand high.

  • We don't want to miss you, Robert.

  • Who's identify yourself to Robert Steinberg.

  • Damn internal medicine.

  • I guess this question is mostly for Dr Elliot.

  • Doctor, sharpen the rest of the panel.

  • What is it?

  • I know not speaking specifically about the situation here, which I don't know all that much about.

  • What do you see is the reasons why health care institutions perhaps have had different responses than other institutions in society.

  • Is that something about health care?

  • Is it something about medicine?

  • It's something about me.

  • Is it something else I can You're on.

  • Uh, yeah, I could take a couple of guesses.

  • You know what I don't have?

  • Ah, I don't have a huge amount of knowledge.

  • One of things that I was thinking about when I was listening.

  • Thio Richard's case, compared to the airline industry, is that health care executions are largely closed.

  • When a plane goes down, you can't hide it.

  • It's very easy to hide things in hospitals and medical schools.

  • Secondly, the entire basis of research oversight in universities is essentially based on trust.

  • You don't have a lot of monitoring of research going, and so when you have an I r B, which is which is responsible for oversight and they're not skeptical at all about what they're hearing from investigators and simply take it as true, then that's a system that's very easy to get.

  • I would agree with you think Hartley, could you speak good baby, because I can you hear me better now?

  • I would agree with many of those comments, I think in addition, there are strong disincentives to increasing transparency in this space to build on Karl's points there.

  • We all hear about the mantra publisher Parish.

  • No margin, no mission.

  • All these sorts of things that are part of the rhetoric of modern academic health centers being more transparent, engaging with members of the community proactively in spaces like this cost time costs, money slows research down.

  • And I think that with regard to all the different financial systems and structures that are in place, there's enormous disincentives to increasing transparency in these kinds of ways.

  • Thank you.

  • Any other comments from the panel?

  • Members would like to address this issue.

  • Any thoughts?

  • Yes.

  • Can you hear me?

  • Yeah.

  • Yeah, I would, uh, I have to say so much of this is sort of case specific that I want to unpack the comments from both of the last two speakers Carl Rich about exactly what sorts of events are we talking about in terms of the systematic improvement of systems within Irbe's and oversights.

  • You know, I do see that as a continuous quality improvement sort of enterprise, a heart being a significant element of how institutions trying maintain standards.

  • One element we haven't talked at all about his day to safety monitoring board that monitor the progress of research and can pick up on unanticipated events.

  • Potentially stop the research at Central City's other elements.

  • They're part of the research enterprise that can respond when you have adverse events that are not anticipated but anticipated.

  • To a certain extent.

  • Some of the cases that we're thinking about here have to do with egregious the behavior of a particular investigator, and I very much agree that it's a harder set of case cases to address.

  • I'm not sure I'd be interested in hearing more about girls examples, but it's hard to draw out.

  • Uh, I think we do need a set of principles and a set of institutional mechanisms to deal with that type of problem, which I see is different than the type of problem that arises when you have a serious adverse event in a research protocol that I do think our systems are reasonably well structured to identify.

  • Yeah, okay.

  • Audience backyard.

  • Go ahead.

  • Yes, please identify yourself to thank you.

  • Good morning, University of Minnesota.

  • I am Caprice Jackson or of the Marcy Homes community.

  • I completed undergraduate and graduate work at Ball State University, MUNCIE, Indiana Although community education is effective mentally ill and or Alzheimer's, patients are hardly likely to give an altered outcome due to their mental capacities or mental incapacity ese.

  • Instead of Alzheimer's patients and the mentally ill who are considered outpatients.

  • Let's use house lefties hospitalize Alzheimer's or mentally challenged persons whose environments are controlled and monitored when whatever adverse testing outcomes surface, they can be introduced to the subject.

  • Treated and addressed in an inappropriate environment, I find the use of outpatient Alzheimer's subjects and the mentally ill challenge to be questionable and contribution to medical research.

  • Thank you.

  • Your response, please.

  • Thank you.

  • Anyone on the panel?

  • So do you want to, like jump in?

  • So first of ill?

  • I think it's important to remember that you can't just say all people with mental illnesses because there is this huge continuum, and even in terms of hospitalization, people are now hospitalized for very long.

  • You know it's an average of eight days, so it would be pretty difficult to conduct research and frankly, from my discussions with people with serious mental illnesses, they really don't want to be in the hospital that much longer.

  • They really want to be back into the community, in their homes on We know that outpatient treatment can be extremely effective for people.

  • Do we need additional, you know, intensive community supports, available supportive housing and things like that?

  • Absolutely.

  • But I honestly just don't think it would work for people.

  • Anyone else?

  • I agree with that.

  • I think that it's important to consider that some of the treatments are very long term treatments in these situations.

  • So, you know, the the A drug, for instance, even a new drug that would try to slow the progression of Alzheimer's could be years in the making and therefore to provide inpatient setting isn't really appropriate to think about what kind of supports we need in the community toe offer.

  • Sufficient protections and support is it is a different issue when the family can't provide it.

  • So I do think we want the least restrictive alternative with a patient.

  • N

We're going to be moving the session now, Thio.

字幕と単語

ワンタップで英和辞典検索 単語をクリックすると、意味が表示されます

B1 中級

パネルディスカッション国民的議論の視点、研究倫理における同意の課題 (Panel: Perspectives on National Debates, Consent Challenges in Research Ethics)

  • 4 0
    林宜悉 に公開 2021 年 01 月 14 日
動画の中の単語